1. Signaling Pathways
  2. Metabolic Enzyme/Protease
    Neuronal Signaling
  3. Adenosine Kinase

Adenosine Kinase

ADK

Adenosine kinase (AK) is a cytosolic enzyme that catalyzes the conversion of adenosine to AMP. One potential adenosine regulating agent (ARA) target is adenosine kinase. Adenosine kinase activation represents the major clearance route of adenosine and is partly responsible for its extremely short plasma half-life (<1 s). Inhibition of adenosine kinase results in increased intracellular adenosine which passes out of the cell via passive diffusion or via nucleoside transporter(s) to activate nearby cell-surface adenosine receptors. Thus, adenosine kinase inhibition can represent an alternative mechanism for activation of adenosine receptors and production of adenosine-associated pharmacologies.

Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Several potent AKIs are shown to exhibit anticonvulsant activity in the rat maximal electric shock (MES) induced seizure assay.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15424
    5-Iodotubercidin
    Inhibitor 99.64%
    5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin.
    5-Iodotubercidin
  • HY-103161
    ABT-702 dihydrochloride
    Inhibitor 99.64%
    ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC50=1.7 nM).
    ABT-702 dihydrochloride
  • HY-148327
    AK-IN-1
    Inhibitor 99.95%
    AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures.
    AK-IN-1
  • HY-19259
    GP3269
    Inhibitor
    GP3269 is a potent, selective, and orally active inhibitor of human adenosine kinase (AK) with an IC50 of 11 nM. GP3269 exhibits anticonvulsant activity in rats.
    GP3269
  • HY-112482A
    ABT-702 hydrochloride
    Inhibitor
    ABT-702 hydrochloride is a potent inhibitor of adenosine kinase with an IC50 of 1.7 nM.
    ABT-702 hydrochloride
  • HY-116005
    A-286501
    Inhibitor
    A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC50 value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents.
    A-286501
Cat. No. Product Name / Synonyms Application Reactivity